Announcing publication of new ESC/EAS dyslipidaemia guidelines

These updated 2016 guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. The guidance includes sections on: the evaluation of laboratory lipid and apolipoprotein parameters; treatment targets; lifestyle modifications to improve the plasma lipid profile; drugs for treatment of hypercholesterolaemia and hypertriglyceridaemia; drugs affecting HDL-cholesterol; managing dyslipidaemias in different clinical settings; monitoring lipids and enzymes in patients on lipid-lowering therapy; and strategies to encourage adoption of healthy lifestyle changes and lipid-modifying therapies.

Publication in full

• Atherosclerosis - available soon
• Eur. Heart J. (2016) 
  DOI: http://dx.doi.org/10.1093/eurheartj/ehw272 First published August 27, 2016
• Download full pdf

Slideset

• Available soon